	US 11,806,322 B2
	Mirdametinib treatment
Uchenna H Iloeje, Stamford, CT (US); Abraham J Langseth, Stamford, CT (US); and Todd Shearer, Stamford, CT (US)
Assigned to SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed by SpringWorks Therapeutics Inc., Stamford, CT (US)
Filed on Mar. 16, 2023, as Appl. No. 18/185,148.
Claims priority of provisional application 63/321,036, filed on Mar. 17, 2022.
Claims priority of provisional application 63/321,046, filed on Mar. 17, 2022.
Prior Publication US 2023/0321013 A1, Oct. 12, 2023
Int. Cl. A61K 31/166 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/166 (2013.01) [A61K 9/0053 (2013.01); A61P 35/00 (2018.01)]

26 Claims

1. A method of treating a human patient 2 years or older who has neurofibromatosis type 1 (NF1) associated inoperable plexiform neurofibromas (PN) comprising orally administering an effective amount of mirdametinib to the patient, wherein an amount of mirdametinib is administered on the first day of treatment to provide an AUC_0-tauless than 300 ng·h/mL.